Trial · NCT03193866
Adverse events273
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 273
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Pneumonia | Infections and infestations | RTX (First or Second Line) | 6 | 1,184 | 6 |
| serious | Pneumonia | Infections and infestations | IFN (First Line) | 0 | 884 | 0 |
| serious | Pneumonia | Infections and infestations | GA (First Line) | 0 | 97 | 0 |
| serious | Pneumonia | Infections and infestations | DMF (First or Second Line) | 0 | 870 | 0 |
| serious | Pneumonia | Infections and infestations | NTZ (First or Second Line) | 0 | 767 | 0 |
| serious | Pneumonia | Infections and infestations | FGL (First Line) | 0 | 384 | 0 |
| serious | Pneumonia | Infections and infestations | TFL (First Line) | 0 | 138 | 0 |
| serious | Malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | RTX (First or Second Line) | 0 | 1,184 | 0 |
| serious | Malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | IFN (First Line) | 0 | 884 | 0 |
| serious | Malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | GA (First Line) | 0 | 97 | 0 |
| serious | Malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | DMF (First or Second Line) | 0 | 870 | 0 |
| serious | Malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | NTZ (First or Second Line) | 0 | 767 | 0 |
| serious | Malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | FGL (First Line) | 1 | 384 | 1 |
| serious | Malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | TFL (First Line) | 0 | 138 | 0 |
| serious | Serum sickness | Immune system disorders | RTX (First or Second Line) | 1 | 1,184 | 1 |
| serious | Serum sickness | Immune system disorders | IFN (First Line) | 0 | 884 | 0 |
| serious | Serum sickness | Immune system disorders | GA (First Line) | 0 | 97 | 0 |
| serious | Serum sickness | Immune system disorders | DMF (First or Second Line) | 0 | 870 | 0 |
| serious | Serum sickness | Immune system disorders | NTZ (First or Second Line) | 0 | 767 | 0 |
| serious | Serum sickness | Immune system disorders | FGL (First Line) | 0 | 384 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03193866/events